Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600211'
s Net Margin % Range Over the Past 10 Years
Min: 9.77 Med: 24.99 Max: 37.46
Current: 32.32
SHSE:600211's Net Margin % is ranked better than 95.95% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs SHSE:600211: 32.32
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Tibet Rhodiola Pharmaceutical Holding Co Net Margin % Related Terms
Tibet Rhodiola Pharmaceutical Holding Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co Net Margin % Chart
Tibet Rhodiola Pharmaceutical Holding Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tibet Rhodiola Pharmaceutical Holding Co Net Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a Net Margin % of 41.28% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. This is 65% above median its historical median of 24.99. Over the past decade, Tibet Rhodiola Pharmaceutical Holding Co's Net Margin % has ranged from 9.77 to 37.46. According to the industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #39 out of 962 companies in the Drug Manufacturers industry, placing it in the top 4.1%.
Is Tibet Rhodiola Pharmaceutical Holding Co's Net Margin % too high?
Tibet Rhodiola Pharmaceutical Holding Co's current Net Margin % of 41.28% is 65% above median its 10-year median of 24.99. Over the past 10 years, this metric has ranged from a low of 9.77 to a high of 37.46. The Drug Manufacturers industry median Net Margin % is 5.56. Tibet Rhodiola Pharmaceutical Holding Co's value of 41.28% is 642.4% above this industry median. Based on the distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #39 out of 962 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #39 out of 962 companies for Net Margin %. This places Tibet Rhodiola Pharmaceutical Holding Co in the top 4% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Tibet Rhodiola Pharmaceutical Holding Co's value of 41.28% is 642.4% above this benchmark. Historically, Tibet Rhodiola Pharmaceutical Holding Co's own Net Margin % has ranged from 9.77 to 37.46 over the past decade. While the company's 10-year median is 24.99 vs. the industry median of 5.56, Tibet Rhodiola Pharmaceutical Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tibet Rhodiola Pharmaceutical Holding Co's current Net Margin % of 41.28% is 642.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tibet Rhodiola Pharmaceutical Holding Co's current Net Margin % is 41.28%, which is 65% above median its own 10-year median of 24.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.53, compared to a current price of ¥39.30 — trading 3% below its estimated fair value. The current Net Margin % is 41.28%, which is 65% above median its 10-year median of 24.99 and 642.4% above the Drug Manufacturers industry median of 5.56. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current Net Margin % is 41.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued.
The current stock price of ¥39.30 is trading 3% below its estimated GF Value™ of ¥40.53.
GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.
Key valuation signals for SHSE:600211:
Net Margin %: 41.28% (65% above median its 10-year median of 24.99)
GF Value™: ¥40.53 vs. price of ¥39.30 (3% below fair value)
Industry Position: 642.4% above the Drug Manufacturers median (#39 of 962)
No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tibet Rhodiola Pharmaceutical Holding Co Business Description
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score
Get the complete analysis for SHSE:600211
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600211 has been successfully added to your 
